Literature DB >> 2598170

A new high-yield continuous cell-culture system for lymphokine-activated killer cells.

T Noto1, Y Tokuda, Y Nakamura, A Suzuki, K Watanabe, M Yamamura, T Tajima, T Mitomi, K Nishijima.   

Abstract

We performed basic studies on a new high-yield culture system (concentrate rotary tissue-culture system) for application to adoptive immunotherapy with lymphokine-activated killer (LAK) cells. Using this system, we demonstrated that up to 2 x 10(7) peripheral blood mononuclear cells/ml could be cultured in interleukin-2 with a sufficient recovery rate and cytotoxicity in short-term cultures (6 days). This system can also be used to proliferate LAK cells to four times the initial cell number with sufficient cytotoxicity for 14 days of culture. Thus, this system allows activation of sufficient numbers of cells to conduct clinical trials on humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598170     DOI: 10.1007/bf01665023

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

2.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

3.  Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.

Authors:  L Kangas; M Grönroos; A L Nieminen
Journal:  Med Biol       Date:  1984

4.  A new compact and cell dense continuous culture system.

Authors:  Y Nakamura; K Watanabe; T Noto; T Tajima; M Yamamura
Journal:  J Immunol Methods       Date:  1989-03-10       Impact factor: 2.303

5.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

6.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

7.  Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.

Authors:  L M Muul; E P Director; C L Hyatt; S A Rosenberg
Journal:  J Immunol Methods       Date:  1986-04-17       Impact factor: 2.303

8.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

  8 in total
  3 in total

1.  A new culture system for the cultivation of mammalian cells for the production of several biologically active substances.

Authors:  M Murata; M Togami; Y Tawara; K Onodera
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

2.  Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.

Authors:  Y Nakamura; Y Tokuda; M Iwasawa; H Tsukamoto; M Kidokoro; N Kobayashi; S Kato; T Mitomi; S Habu; T Nishimura
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

3.  Macrophage-T cell interaction is essential for the induction of p75 interleukin 2 (IL-2) receptor and IL-2 responsiveness in human CD4+ T cells.

Authors:  Y Nakamura; T Nishimura; Y Tokuda; N Kobayashi; K Watanabe; T Noto; T Mitomi; K Sugamura; S Habu
Journal:  Jpn J Cancer Res       Date:  1991-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.